Harmony Biosciences (HRMY) Tops Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates
May 3, 2022 7:30 AM EDTWAKIX® (pitolisant) Net Revenue of $85.3 Million for First Quarter 2022 Increase of 43% vs. the Same Period in 2021
WAKIX Surpasses $500 Million in Cumulative Net Revenue Since Launch
Initiated Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia
Conference Call and Webcast to be Held Today at 8:30 a.m. ETÂ
PLYMOUTH MEETING, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Harmony or the Company) (Nasdaq: HRMY), a pharmaceutical company focused on delivering innovative therapies that improve the health of people living with... More
